A new set of patent applications has been filed by Moleculin Biotech with the FDA regarding annamycin's production and reconstitution, which would protect the company's drug for another 20 years if approved. Annamycin is indicated as a treatment of relapsed or refractory acute myeloid leukemia.
Moleculin submits new annamycin patent applications
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.